{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:03Z","timestamp":1791252783393,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007727","name":"Department of Industry, Innovation and Science, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.05.022","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:24:29Z","timestamp":1749155069000},"page":"e788-e798.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias"],"prefix":"10.1016","volume":"25","author":[{"given":"Mary","family":"Sartor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-1436","authenticated-orcid":false,"given":"Thomas X","family":"Lemarchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Britz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-6761","authenticated-orcid":false,"given":"Rosanne","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-1766","authenticated-orcid":false,"given":"David J","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.05.022_bib0001","series-title":"Serum free light chain analysis plus hevylite","author":"Bradwell","year":"2015"},{"key":"10.1016\/j.clml.2025.05.022_bib0002","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.022_bib0003","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.05.022_bib0004","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2025.05.022_bib0005","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/14712598.2021.1841747","article-title":"Isatuximab for the treatment of relapsed\/refractory multiple myeloma","volume":"20","author":"Richardson","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clml.2025.05.022_bib0006","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/cyto.b.21961","article-title":"CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab","volume":"100","author":"Soh","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2025.05.022_bib0007","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1158\/1078-0432.CCR-16-2870","article-title":"FDA drug approval: elotuzumab in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma","volume":"23","author":"Gormley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.05.022_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"13","key":"10.1016\/j.clml.2025.05.022_bib0009","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2217\/fon-2020-1088","article-title":"Elotuzumab in the treatment of relapsed and refractory multiple myeloma","volume":"17","author":"Grosicki","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2025.05.022_bib0010","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2025.05.022_bib0011","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.05.022_bib0012","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.4049\/jimmunol.1601746","article-title":"Human plasmacytoid dendritic cells display and shed B cell maturation antigen upon TLR engagement","volume":"198","author":"Schuh","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2025.05.022_bib0013","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.022_bib0014","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","article-title":"Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.05.022_bib0015","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.05.022_bib0016","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.05.022_bib0017","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/17474086.2024.2357274","article-title":"Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this?","volume":"17","author":"Martino","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2025.05.022_bib0018","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaad.2023.08.094","article-title":"Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab","volume":"90","author":"Lery","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2025.05.022_bib0019","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/bjh.13298","article-title":"MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide","volume":"169","author":"Asvadi","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.05.022_bib0020","first-page":"316","article-title":"Identification and characterization of lambda myeloma antigen, LMA, as a therapeutic target in lambda type multiple myeloma","volume":"98_s1","author":"Asvadi","year":"2013","journal-title":"Haematologia"},{"key":"10.1016\/j.clml.2025.05.022_bib0021","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.4049\/jimmunol.135.2.1276","article-title":"Structural analysis of the myeloma-associated membrane antigen KMA","volume":"135","author":"Goodnow","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2025.05.022_bib0022","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/0161-5890(85)90062-8","article-title":"Conformation dependence of a monoclonal antibody defined epitope on free human kappa chains","volume":"22","author":"Raison","year":"1985","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clml.2025.05.022_bib0023","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.humimm.2014.08.196","article-title":"Cell membrane associated free kappa light chains are found on a subset of tonsil and in vitro-derived plasmablasts","volume":"75","author":"Hutchinson","year":"2014","journal-title":"Hum Immunol"},{"key":"10.1016\/j.clml.2025.05.022_bib0024","first-page":"1","article-title":"A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and\/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)","volume":"00","author":"Spencer","year":"2023","journal-title":"British J Haematol"},{"issue":"s1","key":"10.1016\/j.clml.2025.05.022_bib0025","first-page":"776","article-title":"Phase 2a, open-label, multi-dose study of anti-kappa monoclonal antibody, MDX-1097, in relapsed kappa-chain restricted multiple myeloma with stable measurable disease","volume":"98","author":"Dunn","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.05.022_bib0026","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-019-0217-5","article-title":"A preliminary study of the anti-\u03ba myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with \u03ba-restricted multiple myeloma","volume":"9","author":"Spencer","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.05.022_bib0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.clml.2025.05.022_bib0028","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2021-148243","article-title":"A novel B cell antigen designated Lambda Myeloma antigen (LMA) has been identified using two fully Human monoclonal antibodies (Mabs) that bind to similar epitopes on plasma cells from patients with plasma cell dyscrasias","volume":"138","author":"Sartor","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.022_bib0029","first-page":"231","article-title":"Sphingolipids in apoptosis","volume":"34","author":"Tirodkar","year":"2012","journal-title":"Exp Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:20:06Z","timestamp":1772727606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025002009"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) on Malignant but Not Normal Plasma Cells Offers Novel Therapeutic Targets for Patients With Myeloma, Amyloidosis and Other Plasma Cell Dyscrasias","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}